产品
编 号：F746809
分子式：C26H28BrClF3N5O2
分子式：C26H28BrClF3N5O2
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1715025-34-5
产品详情
生物活性：
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
体内研究：
ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice.Animal Model:Calu-6 NSCLC xenograft tumor models in mice.
Dosage:50, 75 mg/kg.
Administration:Orally either daily (qd) or every other day (q2d) for 27 days.
Result:Significantly reduced the tumor volume.
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
体内研究：
ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice.Animal Model:Calu-6 NSCLC xenograft tumor models in mice.
Dosage:50, 75 mg/kg.
Administration:Orally either daily (qd) or every other day (q2d) for 27 days.
Result:Significantly reduced the tumor volume.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备